ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: 0299 • ACR Convergence 2022

    Radiographic Change in Patients with Rheumatoid Arthritis and Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc Analysis of Two Phase 3 Trials of Filgotinib

    Yoshiya Tanaka1, Tatsuya Atsumi2, Daniel Aletaha3, Robert Landewé4, Beatrix Bartok5, Alena Pechonkina6, Ling Han6, Kahaku Emoto7, Shungo Kano7, Vijay Rajendran8 and Tsutomu Takeuchi9, 1University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 2Hokkaido University, Sapporo, Japan, 3Medical University Vienna, Wien, Austria, 4Amsterdam University Medical Center, Meerssen, Netherlands, 5Gilead Sciences, Inc., La Jolla, CA, 6Gilead Sciences, Foster City, CA, 7Gilead Sciences, K.K., Tokyo, Japan, 8Galapagos NV, Gent, Belgium, 9Keio University and Saitama Medical University, Tokyo, Japan

    Background/Purpose: In some patients (pts) with rheumatoid arthritis (RA), especially those with joint damage early in the disease, first-line methotrexate (MTX) treatment may not suffice…
  • Abstract Number: 0403 • ACR Convergence 2022

    Efficacy and Safety of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis: 16-Week Results from a Phase 3 Study

    Yu Xue1, Jiankang Hu2, Dongzhou Liu3, Jingyang Li4, Huaxiang Wu5, Chunyu Tan6, Lie Dai7, Mengru Liu8, Hongying Li8 and Hejian Zou1, 1Huashan Hospital affiliated to Fudan University, Shanghai, China, 2Jiangxi Pingxiang People’s Hospital, Shanghai, China, 3Shenzhen People’s Hospital (The Second Clinical Medical College of Jinan University), Shanghai, China, 4Zhuzhou Central Hospital, Shanghai, China, 5The Second Affiliated Hospital Zhejiang University School of Medicine, Shanghai, China, 6West China Hospital of Sichuan University, Shanghai, China, 7Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Shanghai, China, 8Eli Lilly and Company, Shanghai, China

    Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in global clinical trials in patients with radiographic axial spondyloarthritis (r-axSpA)/ankylosing spondylitis…
  • Abstract Number: 0763 • ACR Convergence 2022

    Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis

    Vibeke Strand1, Shaun Bender2 and Dorothy McCabe3, 1Stanford University School of Medicine, Stanford, CA, 2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 3Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT

    Background/Purpose: The VOLTAIRE trials program compared the safety, efficacy, and immunogenicity of biosimilar BI 695501 with adalimumab reference product (RP) for indications including moderate-severely active…
  • Abstract Number: 1037 • ACR Convergence 2022

    Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies

    Xenofon Baraliakos1, Dafna Gladman2, Soumya Chakravarty3, Cinty Gong4, May Shawi5, Emmanouil Rampakakis6, Kishimoto Mitsumasa7, Enrique R Soriano8 and Philip J Mease9, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 3Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 8Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 9Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess the activity of axial disease in patients (pts) with PsA, only…
  • Abstract Number: 1549 • ACR Convergence 2022

    Toward Safer Glucocorticoid Therapy

    Xingyu Pan1, Qiongqiong Hou1, Jiahui Xu1, Yake Ma1, Jiawen Li1, Min Li1, Jing Su1, Xuerou Shi1, William Bracken2 and David Katz2, 1WuXi AppTec, Nantong, China, 2Sparrow Pharmaceuticals, Portland, OR

    Background/Purpose: SPI-62 is a potent 11b-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor entering Phase 2 development as adjunctive therapy to prednisolone in polymyalgia rheumatica, as well…
  • Abstract Number: 1831 • ACR Convergence 2022

    Establishing a Scientific Bridge to Historic VIOXX to Enable a Reintroduction of Rofecoxib: Pharmacokinetic Evaluation of TRM‑201 (Rofecoxib)

    Judith Boice1, Travis Helm1, Maria Bermudez2, Mark Corrigan1 and Bradford Sippy1, 1Tremeau Pharmaceuticals, Inc, Concord, MA, 2Clinical Pharmacology of Miami, LLC, Miami, FL

    Background/Purpose: TRM-201 (rofecoxib) is a cyclooxygenase-2 (COX-2) selective inhibitor being developed for the treatment of hemophilic arthropathy (HA) and acute migraine. Previously marketed as VIOXX,…
  • Abstract Number: 2000 • ACR Convergence 2022

    Tapering of Long-term, Low Dose Glucocorticoids in Senior Rheumatoid Arthritis Patients: Follow up of the Pragmatic, Multicentre, Placebo-controlled GLORIA Trial

    Abdullah Almayali1, Maarten Boers2, Linda Hartman3, Daniela OPRIS-BELINSKI4, Reinhard Bos5, Marc Kok6, Jose Pereira da Silva7, Eduard N Griep8, Ruth Klaasen9, CF Allaart10, Paul Baudoin11, Hennie Raterman12, Zoltan Szekanecz13, Frank Buttgereit14, Pavol MASARYK15, Willem Lems16, Maurizio Cutolo17 and Marieke ter Wee3, 1Amsterdam University Medical Centers, Vrije Universiteit, Purmerend, Noord-Holland, Netherlands, 2Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 3Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, 4Carol Davila University, Bucharest, Romania, 5Medical Centre Leeuwarden, Department of Rheumatology, Leeuwarden, Netherlands, 6Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, 7University of Coimbra, Rheumatology, Columbia, Portugal, 8Department of Rheumatology, Antonius Hospital, Leeuwarden, Netherlands, 9Department of Rheumatology, Meander Medical Center, Amersfoort, Netherlands, 10Leiden University Medical Center, Leiden, Netherlands, 11Reumazorg Flevoland, Almere, Netherlands, 12Department of Rheumatology, Northwest Clinics, Alkmaar, Netherlands, 13Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary, 14Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, 15National Institute for the Rheumatic Diseases, Piešťany, Slovakia, 16Amsterdam University Medical Centers, Amsterdam, Netherlands, 17Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy

    Background/Purpose: Guidelines suggest glucocorticoids (GC) should be used as bridge therapy in rheumatoid arthritis (RA), but many patients are on chronic treatment, and the effects…
  • Abstract Number: 2139 • ACR Convergence 2022

    Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial

    Iain B McInnes1, Philipp Sewerin2, Mohamed Sharaf3, Michela Efficace4, May Shawi5, Michelle Perate6, Miriam Zimmermann7 and Laura Coates8, 1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 3Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 4Janssen Cilag SpA, Imperia, Italy, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6Janssen Scientific Affairs, LLC, Horsham, PA, 7Janssen Scientific Affairs, LLC, Zug, Switzerland, 8Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…
  • Abstract Number: 0036 • ACR Convergence 2022

    Patient-specific and Disease-related Determinants for Cardiovascular Disease (CVD) Risk Stratification in the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Clinical Trial Cohort

    Junjie Peng1, George Robinson1, Stacy P Ardoin2, Laura Schanberg3, Elizabeth Jury1 and Coziana Ciurtin4, 1University College London, London, United Kingdom, 2Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, 3Duke University Medical Center, Durham, NC, 4Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, United Kingdom

    Background/Purpose: The risk of developing cardiovascular disease (CVD) through atherosclerosis in juvenile-onset systemic lupus erythematosus (JSLE) patients is significantly increased. This study aimed to stratify…
  • Abstract Number: 0304 • ACR Convergence 2022

    Rheumatoid Arthritis Patients Who Switched Treatment from Adalimumab to Upadacitinib Demonstrate a Robust Reduction of Inflammation-related Biomarkers: Proteomics Analysis from the SELECT-COMPARE Phase 3 Study

    Thierry Sornasse1, Fang Cai2, Heidi Camp3, In-Ho Song4 and Iain B McInnes5, 1AbbVie, South San Francisco, CA, 2AbbVie, Redwood City, CA, 3Abbvie, Winnetka, IL, 4AbbVie, Inc., North Chicago, IL, 5Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom

    Background/Purpose: Upadacitinib 15 mg QD (UPA), an oral JAK inhibitor, showed greater efficacy compared to adalimumab (ADA) in patients (pts) with active rheumatoid arthritis (RA)…
  • Abstract Number: 0411 • ACR Convergence 2022

    Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study

    Désirée van der Heijde1, Xenofon Baraliakos2, Maxime Dougados3, Matthew Brown4, Denis Poddubnyy5, Filip Van den bosch6, Nigil Haroon7, Huji Xu8, Tetsuya Tomita9, Lianne Gensler10, Marga Oortgiesen11, Carmen Fleurinck12, Natasha de Peyrecave13, Thomas Vaux14, Alexander Marten15 and Atul Deodhar16, 1Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 2Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 3Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, 4Genomics England, London, United Kingdom, 5Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 6Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, 7Schroeder Arthritis Institute, University Health Network; University of Toronto, Toronto, ON, Canada, 8Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China, 9Department of Orthopaedic Biomaterial Science, Osaka University Graduate School of Medicine, Osaka, Japan, Suita Osaka, Japan, 10Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, 11UCB Pharma, Raleigh, NC, 12UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, 13UCB Pharma, Brussels, Belgium, 14UCB Pharma, Slough, United Kingdom, 15UCB Pharma, Monheim am Rhein, Germany, 16Oregon Health & Science University, Portland, OR, USA, Portland, OR

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In a phase 2b study, BKZ showed rapid and…
  • Abstract Number: 0890 • ACR Convergence 2022

    Long Term Efficacy of a 2-year MRI Treat-to-target Treatment Strategy on Disease Activity, MRI Inflammation and Physical Function in Rheumatoid Arthritis Patients in Clinical Remission: Five Year Follow-up of the IMAGINE-RA Cohort

    Signe Møller-Bisgaard1, Kim Hørslev-Petersen2, Daniel Glinatsi3, Bo Ejbjerg4, Merete Lund Hetland5, Jakob Møllenbach Møller6, Robin Christensen7, Sabrina Mai Nielsen8, Mikael Boesen9, Kristian Stengaard-Pedersen10, Ole Rintek Madsen11, Bente Jensen12, Jan Alexander Villadsen13, Ellen Margrethe Hauge10, Oliver Hendricks2, Hanne Merete Lindegaard14, Niels Steen Krogh15, Anne Grethe Jurik16, Henrik Thomsen17 and Mikkel Østergaard18, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 2Department of Rheumatology, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 3Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 4Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, 5Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, 6Department of Radiology, Herlev-Gentofte Hospital, Copenhagen, Denmark, 7Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 8The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, 9Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark, 10Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 11Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Herlev-Gentofte, Copenhagen, Denmark, 12Center for Rheumatology and Spine Diseases, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark, 13Department of Rheumatology, Silkeborg Hospital, Silkeborg, Denmark, 14Department of Rheumatology, Odense University Hospital, Odense, Denmark, 15ZiteLab ApS, Frederiksberg, Denmark, 16Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, 17Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark, 18Rigshospitalet, University of Copenhagen, Glostrup, Denmark

    Background/Purpose: Targeting MRI remission in rheumatoid arthritis (RA) patients in clinical remission may improve long term clinical, functional and MRI outcomes. The purpose of the…
  • Abstract Number: 1077 • ACR Convergence 2022

    Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials

    Pirow Bekker1, Peter Merkel2 and David Jayne3, 1ChemoCentryx, San Juan Capistrano, CA, 2U of Pennsylvania, Philadelphia, PA, 3University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: Avacopan is approved as adjunctive treatment for adults with ANCA-associated vasculitis (AAV). This study aimed to combine and report on data of the safety…
  • Abstract Number: 1579 • ACR Convergence 2022

    The TICOG Study: Tight Control of Gout – A Randomized, Controlled Trial of Targeted versus Conventional Treatment for Gout Including Ultrasonography

    Sarah Black, Natalie McKee, Jonathan McKnight, Annmarie McShane, Adrian Pendleton, Taggart Alister and Gary Wright, Musgrave Park Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom

    Background/Purpose: Gout is a common inflammatory arthritis triggered by deposition of monosodium urate crystals in joints, bone and soft tissues, with a prevalence of 1-4%…
  • Abstract Number: 1832 • ACR Convergence 2022

    Efficacy and Safety Similarity of Biosimilar Adalimumab-aqvh to Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Phase III Study

    Barbara Finck, Helen Tang, Kathy Jensen, Francesca Civoli and Suzanna Tatarewicz, Coherus BioSciences, Redwood City, CA

    Background/Purpose: This study aimed to demonstrate that there were no clinically meaningful differences between adalimumab-aqvh, a US Food and Drug Administration–approved biosimilar, and adalimumab in…
  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology